Premaitha Share Discussion Threads

[twix386] 24/2/2017 08:59

Dave444

answered above as just updated post.

Supply us any further details if you really want to be accurate.
Would have thought that would be obvious to any helpful poster.

I expect that's the full story out now and no drama. Just planting doubt without offering info - again.

[hjb1] 24/2/2017 08:58

dave, what are you on about? just copied as Twix said, what's YOUR problem/agenda then? I wonder !!??
Feel free to supply the missing bit, whenever you like..

[dave444] 24/2/2017 08:55

TWIXTry the full article which I have read this morning!I like to be accurate

[twix386] 24/2/2017 08:48

dave444,

being the helpful chap, perhaps you could supply that comment as appears it was copied from LSE poster and is complete from there? or anyone with access to source material.

One can spot a knocker with a bias without providing the missing info - again!!
No info makes for maximm doubt though eh.

I cannot read the subscription article but the title states "The firm has seen a small handful of false positives for the test in thousands of samples run since the study, but attributed them to biological features."

That's still overall a very impressive Genomeweb write-up and set of test results. Thanks Dave444

[dave444] 24/2/2017 08:35

Hjb1 - I notice you missed out the false positives that were reported in that article - I wonder why?

[timojelly] 24/2/2017 05:33

Getting interested other side of the pond in little old premaitha I see.

[hjb1] 23/2/2017 08:46

NEW YORK (GenomeWeb) – Premaitha Health has reported that its cell-free DNA-based screen for fetal aneuploidies performed with perfect sensitivity and specificity.

Trisomies 13, 18, and 21 have been increasing in incidence, according to the US Centers for Disease Control and Prevention. But, common screening approaches based on ultrasound findings and other markers have false-positive rates that lead many women to seek an invasive diagnostic procedure like an amniocentesis or chorionic villus sampling when it may not be necessary.

Noninvasive prenatal testing (NIPT) providers — which include Roche's Ariosa, BGI, Illumina, Natera, and Laboratory Corporation of America's Sequenom, in addition to Premaitha and others — say that screening with their tests might bring the numbers of invasive tests performed down by identifying women at the highest risk.

As they reported in Fetal Diagnosis and Therapy this month, Premaitha researchers built an automated next-generation sequencing-based workflow and relied on a cohort of almost 250 high-risk women to develop an algorithm to determine the likelihood of trisomies from circulating fetal DNA. When they gauged their algorithm's sensitivity and specificity on a separate cohort, the researchers reported that their CE-marked in vitro diagnostic test, called Iona, had 100 percent specificity and sensitivity.

"We set out to build a test that could be used by [local labs] and that technicians in two weeks could learn to do genetic testing," William Denman, Premaitha’s chief medical officer said in an interview. "That's why writing this paper was important — to show that we've accomplished that."

Premaitha launched its Iona test in February 2015. Cell-free DNA is extracted from the blood samples and fetal DNA is isolated for sequencing on Life Technology's Ion Proton platform. The results are then fed into Iona's bioinformatics pipeline.

Denman added that the test could be run in a local biochemistry lab without the need for highly trained genetics technicians, and that from extraction to analysis, the test takes three days.

As described in the paper, to develop that screening algorithm, the Premaitha team used a set of 239 samples from women at high risk of trisomies. After excluding four samples — three lacked corresponding invasive diagnostic test results and one was from a woman found to have cancer — this algorithm development set included 36 trisomy 21, 26 trisomy 18, and four trisomy 13 samples.

They tested the model they developed on a separate set of 111 samples, though one sample failed the fetal fraction validity check. They reported that all the Iona-based results matched those provided by amniocentesis or chorionic villus sampling, giving 100 percent sensitivity and specificity.

[hjb1] 22/2/2017 23:58

interesting:

Anybody got access to this who can provide a bit more detail/summary?

Premaitha Reports 100 Percent Sensitivity, Specificity for Iona NIPT Test
Feb 22, 2017 | Ciara Curtin

[hjb1] 22/2/2017 19:00

and many many more new customer announcements too, not forgetting a good conclusion to the Genoma debacle.
I gather that Genoma are still apparently selling the IONA test..hmmm?

[gooosed] 22/2/2017 13:52

So next news expected to be Yourgene deal confirmed . . . . then what ? Writ hearings?

[thinkbig?] 22/2/2017 13:13

Ha ha ha ha ha ha

[kaka47] 22/2/2017 12:50

thinkBIG case BUY HIGH sell low

[hamidahamida] 21/2/2017 09:02

Buy low sell high traders dream stock

[hamidahamida] 21/2/2017 08:57

Happy days

[kaka47] 21/2/2017 08:56

Good things come to those who wait patiently IMPATIENT PEOPLE ARE THE BIG LOSERS

[timojelly] 21/2/2017 08:56

There is only one way this is going.... Into the 20's pre writ.

[kaka47] 21/2/2017 08:54

thinkBigYou must feel like a clown selling out on a big loss

[thinkbig?] 21/2/2017 08:31

Well after all this time we are in forward motion. In positive territory as well. All negativity gone

[elrico] 20/2/2017 19:10

Premaitha has provided an update on its activities in the Middle East.
Momentum is building in a region where NIPT is being adopted by all,
rather than high risk women, and where there is clear freedom to operate as
Illumina has no patents in these markets. Three new laboratories are
expected to come on stream by late 2017, with samples initially being
processed at its Manchester facility and St George’s Hospital in London,
whilst laboratory installations are carried out. Together with previous
February announcements of four new laboratory contracts, these contract
wins take the total number of customer labs to 22, up from 4 at end FY 2016
and 8 at end H1 FY 2017, respectively. We maintain our target price of 18p.

Finncap
20/02/17

[hjb1] 20/2/2017 17:10

broker's note Finncap has this at 18p...shouldn't take long!

[swiftnick] 20/2/2017 09:05

MM, the next financial year starts in six weeks' time.

[whites123] 20/2/2017 08:45

I was here from the Vialogy days.
Taking advantage of all offers along the way and growing to like NIPT from the offset.

Remember getting quite excited when it popped through 30p days and talk of multi bagging and big pharma s who would eventually snap it up.

Then the fateful day the Patent Infringement suit was announced.
And since then it has never recovered, despite a great rebuttal from the Board and despite confidence shown on winning by funding promises, despite II taking stock.

Now, with the spread and uptake of Iona exceeding expectations, and being that the Intellectual property disputes are unaffected by the Middle East uptake, is it now time to rejoice?

Take up by PI's is extremely limited..

But looking forward now to a vastly improved share price.


::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Manchester, UK - 20 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, is pleased to announce significant commercial progress in the Middle East through its distribution network.



Premaitha has appointed distributors across the Middle East and these partners have signed a number of new Middle Eastern customers which in aggregate are expected to generate over 10,000 samples per annum, once fully operational. The region offers greater intellectual property freedom, is attracted to the high quality in vitro diagnostic solution offered by Premaitha and is rapidly adopting non-invasive prenatal testing ("NIPT") as a general screening test.



United Arab Emirates ("UAE") and Saudi Arabia

Premaitha has appointed IgBioSystems ("IgBio") as a distributor for the IONA® test in the UAE and Saudi Arabia. IgBio has already secured its first customer in Dubai, which will initially send samples to Premaitha in Manchester before installation of its own laboratory later in 2017. Once installation is complete, the Dubai laboratory will act as a regional hub, processing samples from other hospitals in its local network and from West Africa where it has significant connections.



IgBio has also secured a customer in Saudi Arabia that will be looking to install a service laboratory later this year. Samples will initially be sent to St George's Hospital in London while the laboratory is undergoing set-up and installation.



Kuwait

Premaitha has also appointed a distributor in Kuwait which has secured its first customer. This customer will initially send samples to Manchester, and it is anticipated that demand for the services will result in a full laboratory installation in Kuwait later in 2017.



Intellectual Property landscape

The patents being asserted against Premaitha in the ongoing UK litigation are not present in the Middle East.



NIPT adoption

NIPT is being rapidly adopted across the Middle East for all pregnant women, in contrast to the high-risk focus of public programmes in Europe. This creates a sizeable target addressable market which is attracting high quality service providers who are keen to establish in-house laboratories using Premaitha's IONA® test technology.



Premaitha's IONA® test estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The test is performed on a maternal blood sample, containing traces of fetal DNA, which is then analysed using next generation DNA sequencing technology. The test is highly accurate and significantly reduces the number of women who are unnecessarily subjected to risky, invasive follow up procedures to diagnose Down's syndrome and other genetic conditions.



Dr Stephen Little, CEO of Premaitha Health, commented: "We are pleased to report increasing traction in the Middle East, where our existing installations are exceeding expectations and where we are seeing strong demand in local hospitals through our distributor network. This is a strategically important region which is unaffected by ongoing intellectual property disputes and therefore further de-risks the Company's position in this regard.



"It is clear that there is increasing recognition of the benefits of NIPT as a general screening test in the region and this in turn is driving demand for the IONA® test as a complete in-house solution. The financial impact from these contracts will build during our next financial year creating a strong platform for recurring revenues in the years ahead. The Middle East is positioning itself as a leading global healthcare destination and we are rapidly establishing a significant market presence in the region."



This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

[twix386] 20/2/2017 08:35

yer yer mickymouse

and a funding from HARWOOD secured at much better terms than you thought possible and they are not flipers - into sticky hands.

All looking much better imv and any objective poster would admit it. Nothing like your doom laiden views because each time you profer one it gets trashed by events. lol

[gooosed] 20/2/2017 08:27

So now we settle down to the run up to our day(s)in court.